Profound Medical Business Summary

Profound Medical Corp. (PROF) is a commercial-stage medical device company specializing in incision-free, image-guided robotic ablation therapies. The company generates revenue through a hybrid model consisting of capital equipment sales of its flagship TULSA-PRO and Sonalleve systems, supplemented by high-margin recurring revenue from one-time-use consumables and service contracts. Its primary business segments focus on the TULSA-PRO system, which utilizes real-time MRI and transurethral ultrasound for prostate tissue ablation, and the Sonalleve platform for treating uterine fibroids and bone metastases. Within the competitive landscape, Profound Medical competes directly with PROCEPT BioRobotics, Sonablate Corp., HistoSonics, and Merit Medical Systems. The company distinguishes itself as a pioneer in the "Modern Treatment Pathway," positioning its TULSA-PRO technology as a versatile, radiation-free alternative capable of treating the full spectrum of prostate disease while superiorly preserving patient functional outcomes compared to traditional surgery. Founded in 2008 by Boudino de Jong, Joseph DeJonge, and Dr. Rajiv Chopra based on technology from Sunnybrook Health Sciences Centre, the company is led by Chairman and CEO Dr. Arun Menawat, who previously scaled Novadaq Technologies to a $700 million acquisition by Stryker. The executive team includes President Dr. Mathieu Burtnyk, the primary inventor of the TULSA-PRO algorithm, CFO Rashed Dewan, and Chief Commercial Officer Tom Tamberrino. This leadership group brings deep pedigree from industry leaders such as Cedara Software and Novadaq. Profound is backed by notable institutional investors including the Business Development Bank of Canada (BDC), Genesys Capital, and Raymond James Ltd., with a board of directors featuring experienced medical technology executives like Brian Ellacott and Dr. Arthur Rosenthal.